In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biopharma Quarterly Dealmaking Statistics, Q4 2018

A look at financing, M&A and alliance activity October-December 2018

Executive Summary

At $10.9bn, biopharma financing was at its lowest quarter of the year. GSK’s $5.1bn acquisition of oncology player Tesaro led M&As. And 13 partnerships exceeded the $1bn mark, led by two agreements focused on RNAi.


Related Content

IPO Update: Returns Run Red For Most Biopharma Firms That Went Public In The US Last Year
Bristol-Myers Squibb Sells French Consumer Health Unit UPSA To Taisho For $1.6bn
Astellas Exercises Option To Acquire Potenza, For Up To $405m
Mallinckrodt Creating Two Companies: Generics And Innovative Specialty Drugs
GSK Embraces PARP Promise With Tesaro Buy
Strong Innovent IPO Restoring Faith In HK Biotech Listings?
Cerevel Launches With Pfizer's Early CNS Assets And $350m From Bain Capital
Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy
J&J Bets Big On Arrowhead’s Early Promise In Hepatitis B
Gottlieb: Epidiolex Approval Covers One Specific Cannabidiol Medication, Not Marijuana


Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts